


What is claimed is:

[Claim 1]

A compound represented by the following general formula (I):

[Formula 1]



(wherein R¹ represents hydrogen; C₁₋₁₀ alkyl; C₆₋₁₀ aryl; C₂₋₆ alkenyl; cycloalkylalkyl where the cycloalkyl moiety has 3 to 6 carbon atoms, and the alkylene moiety has 1 to 5 carbon atoms; aralkyl where the aryl moiety has 6 to 10 carbon atoms, and the alkylene moiety has 1 to 5 carbon atoms; C₃₋₆ cycloalkyl; or heteroarylalkyl where the heteroaryl moiety contains 1 to 4 heteroatoms selected from N, O and S as ring-constituting atoms, and the alkylene moiety has 1 to 5 carbon atoms,

R² represents 5- to 7-membered heterocyclic ring containing 1 to 4 heteroatoms selected from N and, O and S and at least one carbon atom as ring-constituting atoms, containing at least one set of adjacent ring-constituting atoms bound by a double bond, and further substituted with at least one oxo group; or a heterocyclic ring consisting of the foregoing heterocyclic ring and a benzene ring condensed thereto; or pyridine 1-oxide;

R² binds to Y via a carbon atom as a ring-constituting atom of R²,

R³, R⁴, and R⁵, which are the same or different, represent hydrogen; hydroxy; halogen; cyano; carbamoyl; C₁₋₆ alkoxy; C₆₋₁₀ aryloxy; C₁₋₆ alkanoyloxy; nitro; amino; C₁₋₈ alkylamino; C₆₋₁₀ arylamino; or acylamino where the acyl moiety has 2 to 6 carbon atoms,

R^{6a} and R^{6b}, which are the same or different, represent hydrogen; fluorine; or hydroxy, or

R^{6a} and R^{6b} combine together to represent =O,

R⁷ and R⁸, which are the same or different, represent hydrogen; fluorine; or hydroxy,

R⁹ and R¹⁰, which are the same or different, represent hydrogen; C₁₋₆ alkyl; C₆₋₁₀ aryl; heteroaryl containing 1 to 4 heteroatoms selected from N, O and S as ring-constituting atoms; aralkyl where the aryl moiety has 6 to 10 carbon atoms, and the alkylene moiety has 1 to 5 carbon atoms; heteroarylalkyl where the heteroaryl moiety contains 1 to 4 heteroatoms selected from N, O and S as ring-constituting atoms, and the alkylene moiety has 1 to 5 carbon atoms; cycloalkylalkyl where the cycloalkyl moiety has 3 to 6 carbon atoms, and the alkylene moiety has 1 to 5 carbon atoms; or C₂₋₆ alkenyl,

X represents O or CH₂, and

Y represents C(=O),

provided that the C₁₋₁₀ alkyl as R¹; the alkylene moiety and cycloalkyl moiety of the cycloalkylalkyl where the cycloalkyl moiety has 3 to 6 carbon atoms, and the alkylene moiety has 1 to 5 carbon atoms as R¹; the alkylene moiety of the aralkyl where the aryl moiety has 6 to 10 carbon atoms, and the alkylene moiety has 1 to 5 carbon atoms as R¹; and the alkylene moiety of the heteroarylalkyl where the heteroaryl moiety contains 1 to 4 heteroatoms selected from N, O and S as ring-constituting atoms, and the alkylene moiety has 1 to 5 carbon atoms as R¹ may be substituted with at least one substituent selected from

1 to 6 halogens; hydroxy; C₁₋₆ alkoxy; C₆₋₁₀ aryloxy; C₁₋₆ alkanoyl; C₁₋₆ alkanoyloxy; carboxyl; alkoxycarbonyl where the alkoxy moiety has 1 to 6 carbon atoms; carbamoyl; alkylcarbamoyl where the alkyl moiety has 1 to 6 carbon atoms; dialkylcarbamoyl where each alkyl moiety has 1 to 6 carbon atoms; alkylsulfonyl where the alkyl moiety has 1 to 6 carbon atoms; aminosulfonyl; alkylsulfinyl where the alkyl moiety has 1 to 6 carbon atoms; alkylthio where the alkyl moiety has 1 to 6 carbon atoms; C₁₋₆ alkoxy substituted with 1 to 6 halogens; and arylcarbonyl where the aryl moiety has 6 to 10 carbon atoms,

the C₆₋₁₀ aryl as R¹; the aryl moiety of the aralkyl where the aryl moiety has 6 to 10 carbon atoms, and the alkylene moiety has 1 to 5 carbon atoms as R¹; the aryl moiety of the C₆₋₁₀ aryloxy as R³, R⁴, or R⁵; the aryl moiety of the C₆₋₁₀ arylamino as R³, R⁴, or R⁵; the C₆₋₁₀ aryl as R⁹ or R¹⁰; the heteroaryl containing 1 to 4 heteroatoms selected from N, O and S as ring-constituting atoms as R⁹ or R¹⁰; the aryl moiety of the aralkyl where the aryl moiety has 6 to 10 carbon atoms, and the alkylene moiety has 1 to 5 carbon atoms as R⁹ or R¹⁰; and the heteroaryl moiety of the heteroarylalkyl where the heteroaryl moiety contains 1 to 4 heteroatoms selected from N, O and S as ring-constituting atoms, and the alkylene moiety has 1 to 5 carbon atoms as R⁹ or R¹⁰ may be substituted with at least one substituent selected from

C₁₋₆ alkyl; C₁₋₆ alkoxy; C₁₋₆ alkanoyloxy; hydroxy; alkoxy carbonyl where the alkoxy moiety has 1 to 6 carbon atoms; carbamoyl; alkyl carbamoyl where the alkyl moiety has 1 to 6 carbon atoms; dialkyl carbamoyl where each alkyl moiety has 1 to 6 carbon atoms; halogen; nitro; cyano; C₁₋₆ alkyl substituted with 1 to 3 halogens; C₁₋₆ alkoxy substituted with 1 to 3 halogens; phenyl; heteroaryl containing 1 to 4 heteroatoms selected from N, O and S as ring-constituting atoms; phenoxy; phenylalkyl where the alkyl has 1 to 3 carbon atoms; and methylenedioxy,

the heterocyclic ring as R² may have, besides the oxo group, the substituents that the C₆₋₁₀ aryl as R¹ mentioned above may have,

when R¹ is C₁₋₁₀ alkyl, it may be substituted with NR¹¹R¹², where R¹¹ and R¹², which are the same or different, represent hydrogen; C₁₋₁₀ alkyl; or aralkyl where the aryl moiety has 6 to 10 carbon atoms, and the alkylene moiety has 1 to 5 carbon atoms; or R¹¹, R¹², the nitrogen atom to which R¹¹ and R¹² bind, and optionally, 1 or 2 heteroatoms may combine together to form a 5- to 7-membered ring, and the alkylene moiety of the aralkyl where the aryl moiety has 6 to 10 carbon atoms, and the alkylene moiety has 1 to 5 carbon atoms as R¹ may be substituted with at least one substituent selected from phenyl, and C₁₋₆ alkyl substituted with 1 to 3 halogens), a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof.

[Claim 2]

The compound, a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to claim 1, wherein R¹ is C₁₋₁₀ alkyl; cycloalkylalkyl where the cycloalkyl moiety has 3 to 6 carbon atoms, and the alkylene moiety has 1 to 5 carbon atoms; or aralkyl where the aryl moiety has 6 to 10 carbon atoms, and the alkylene moiety has 1 to 5 carbon atoms.

[Claim 3]

The compound, a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to claim 1-~~or 2~~, wherein R¹ is cycloalkylalkyl where the cycloalkyl moiety has 3 to 6 carbon atoms, and the alkylene moiety has 1 to 5 carbon atoms;

wherein R¹ is C₂₋₆ alkyl substituted with hydroxy; C₁₋₆ alkyl substituted with 1 to 6 halogens; or C₂₋₆ alkyl substituted with C₁₋₆ alkoxy; or wherein R¹ is allyl, fluoropropyl, 2-[pyridin-3-yl]ethyl, 2-[methylsulfonyl]ethyl, or 2-[aminosulfonyl]ethyl.

~~[Claim 4]~~

~~—The compound, a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to claim 1, wherein R¹ is C₂₋₆ alkyl substituted with hydroxy; C₁₋₆ alkyl substituted with 1 to 6 halogens; or C₂₋₆ alkyl substituted with C₁₋₆ alkoxy.~~

~~[Claim 5]~~

~~—The compound, a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to claim 1, wherein R¹ is allyl, fluoropropyl, 2-(pyridin-3-yl)ethyl, 2-(methylsulfonyl)ethyl, or 2-(aminosulfonyl)ethyl.~~

~~[Claim 6]~~

~~—The compound, a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to any one of claims 1 to 5, wherein R² is a 5- to 7-membered heterocyclic ring containing 1 to 4 heteroatoms selected from N, O and S and at least one carbon atom as ring-constituting atoms, containing at least one set of adjacent ring-constituting atoms bound by a double bond, and further substituted with at least one oxo group; or a heterocyclic ring consisting of the foregoing heterocyclic ring and a benzene ring condensed thereto.~~

~~[Claim 47]~~

The compound, a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to any one of claims 1 to 36, wherein R² is pyridine 1-oxide, which may be substituted with 1 to 4 substituents selected from C₁₋₁₀ alkyl substituted with 1 to 3 fluorine atoms, and unsubstituted C₁₋₁₀ alkyl;

wherein R² is pyridin-2(1H)-one, which may be substituted with 1 to 4 substituents selected from C₁₋₁₀ alkyl substituted with 1 to 3 fluorine atoms, and unsubstituted C₁₋₁₀ alkyl;

wherein R² is pyridin-4(1H)-one, which may be substituted with 1 to 4 substituents selected from C₁₋₁₀ alkyl substituted with 1 to 3 fluorine atoms, and unsubstituted C₁₋₁₀ alkyl;

wherein R² is pyridazin-3(2H)-one, which may be substituted with 1 to 3 substituents selected from C₁₋₁₀ alkyl substituted with 1 to 3 fluorine atoms, and unsubstituted C₁₋₁₀ alkyl;

wherein R² is pyrazin-2(1H)-one, which may be substituted with 1 to 3 substituents selected from C₁₋₁₀ alkyl and C₁₋₁₀ alkyl substituted with 1 to 3 fluorine atoms;

wherein R² is 4H-pyran-4-one, or 2H-pyran-2-one, which may be substituted with 1 to 3 substituents selected from C₁₋₁₀ alkyl substituted with 1 to 3 fluorine atoms, and unsubstituted C₁₋₁₀ alkyl;

wherein R² is quinolin-2(1H)-one, which may be substituted with 1 to 3 substituents selected from C₁₋₁₀ alkyl substituted with 1 to 3 fluorine atoms, and unsubstituted C₁₋₁₀ alkyl; or

wherein R² is pyrimidin-4(3H)-one, or pyrimidine-2,4(1H,3H)-dione, which may be substituted with 1 to 3 substituents selected from C₁₋₁₀ alkyl substituted with 1 to 3 fluorine atoms, and unsubstituted C₁₋₁₀ alkyl.

[Claim 58]

The compound, a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to any one of claims 1 to 47, wherein R² is pyridine 1-oxide;

wherein R² is pyridin-2(1H)-one; 1-(C₁₋₆ alkyl)pyridin-2(1H)-one; or 6-(C₁₋₆ alkyl)pyridin-2(1H)-one;

wherein R² is pyridin-4(1H)-one, or 1-(C₁₋₆ alkyl)pyridin-4(1H)-one;

wherein R² is pyridazin-3(2H)-one;

wherein R² is 4H-pyran-4-one, or 2H-pyran-2-one;

wherein R² is quinolin-2(1H)-one;

wherein R² is pyrimidin-4(3H)-one, or pyrimidine-2,4(1H,3H)-dione.;

[Claim 9]

~~—The compound, a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to any one of claims 1 to 6, wherein R² is pyridin-2(1H)-one, which may be substituted with 1 to 4 substituents selected from C₁₋₁₀ alkyl substituted with 1 to 3 fluorine atoms, and unsubstituted C₁₋₁₀ alkyl.~~

[Claim 10]

~~—The compound, a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to any one of claims 1 to 6, and 9, wherein R² is pyridin-2(1H)-one; 1-(C₁₋₆ alkyl)pyridin-2(1H)-one; or 6-(C₁₋₆ alkyl)pyridin-2(1H)-one.~~

[Claim 11]

~~—The compound, a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to any one of claims 1 to 6, wherein R² is pyridin-4(1H)-one, which may be substituted with 1 to 4 substituents selected from C₁₋₁₀ alkyl substituted with 1 to 3 fluorine atoms, and unsubstituted C₁₋₁₀ alkyl.~~

[Claim 12]

~~—The compound, a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to any one of claims 1 to 6, and 11, wherein R² is pyridin-4(1H)-one, or 1-(C₁₋₆ alkyl)pyridin-4(1H)-one.~~

[Claim 13]

~~—The compound, a tautomer or stereoisomer of the compound, or a pharmaceutically~~

~~acceptable salt thereof, or a solvate thereof according to any one of claims 1 to 6, wherein R² is pyridazin-3(2H)-one, which may be substituted with 1 to 3 substituents selected from C₁₋₁₀-alkyl substituted with 1 to 3 fluorine atoms, and unsubstituted C₁₋₁₀-alkyl.~~

~~[Claim 14]~~

~~———The compound, a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to any one of claims 1 to 6, and 13, wherein R² is pyridazin-3(2H)-one.~~

~~[Claim 15]~~

~~———The compound, a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to any one of claims 1 to 6, wherein R² is pyrazin-2(1H)-one, which may be substituted with 1 to 3 substituents selected from C₁₋₁₀-alkyl and C₁₋₁₀-alkyl substituted with 1 to 3 fluorine atoms.~~

~~[Claim 16]~~

~~———The compound, a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to any one of claims 1 to 6, and 15, wherein R² is pyrazin-2(1H)-one.~~

~~[Claim 17]~~

~~———The compound, a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to any one of claims 1 to 6, wherein R² is 4H-pyran-4-one, or 2H-pyran-2-one, which may be substituted with 1 to 3 substituents selected from C₁₋₁₀-alkyl substituted with 1 to 3 fluorine atoms, and unsubstituted C₁₋₁₀-alkyl.~~

~~[Claim 18]~~

~~———The compound, a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to any one of claims 1 to 6, and 17, wherein R² is 4H-pyran-4-one, or 2H-pyran-2-one.~~

~~[Claim 19]~~

~~———The compound, a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to any one of claims 1 to 6, wherein R² is quinolin-2(1H)-one, which may be substituted with 1 to 3 substituents selected from C₁₋₁₀-alkyl substituted with 1 to 3 fluorine atoms, and unsubstituted C₁₋₁₀-alkyl.~~

~~[Claim 20]~~

~~———The compound, a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to any one of claims 1 to 6, and 19, wherein R² is quinolin-2(1H)-one.~~

~~[Claim 21]~~

~~—The compound, a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to any one of claims 1 to 6, wherein R² is pyrimidin-4(3H)-one, or pyrimidine-2,4(1H,3H)-dione, which may be substituted with 1 to 3 substituents selected from C₁₋₁₀-alkyl substituted with 1 to 3 fluorine atoms, and unsubstituted C₁₋₁₀-alkyl.~~

~~[Claim 22]~~

~~—The compound, a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to any one of claims 1 to 6, and 21, wherein R² is pyrimidin-4(3H)-one, or pyrimidine-2,4(1H,3H)-dione.~~

[Claim ~~623~~]

The compound, a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to any one of claims 1 to ~~522~~, wherein X is CH₂.

[Claim ~~724~~]

The compound, a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to any one of claims 1 to ~~623~~, wherein one of R³ and R⁴ is hydroxy, and the other is hydrogen.

[Claim ~~825~~]

The compound, a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to any one of claims 1 to ~~723~~, wherein R³ is halogen; cyano; carbamoyl; C₁₋₆ alkoxy; C₁₋₆ alkanoyloxy; amino; or acylamino where the acyl moiety has 2 to 6 carbon atoms, R⁴ is hydrogen or hydroxy, and R⁵ is hydrogen,

wherein R³ is hydroxy; carbamoyl; or C₁₋₆ alkanoyloxy, R⁴ is hydrogen, and R⁵ is hydrogen;

wherein R³ is hydroxy, R⁴ is hydrogen, and R⁵ is hydrogen; or

wherein all of R³, R⁴, and R⁵ are hydrogens.

~~[Claim 26]~~

~~—The compound, a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to any one of claims 1 to 23, wherein R³ is hydroxy; carbamoyl; or C₁₋₆ alkanoyloxy, R⁴ is hydrogen, and R⁵ is hydrogen.~~

~~[Claim 27]~~

~~—The compound, a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to any one of claims 1 to 23, wherein R³ is hydroxy, R⁴ is hydrogen, and R⁵ is hydrogen.~~

~~[Claim 28]~~

~~—The compound, a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to any one of claims 1 to 23, wherein all of R³, R⁴, and R⁵ are hydrogens.~~

[Claim ~~929~~]

The compound, a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to any one of claims 1 to ~~828~~, wherein all of R^{6a}, R^{6b}, R⁷, R⁸, R⁹, and R¹⁰ are hydrogens.

[Claim ~~1030~~]

The compound represented by the aforementioned general formula (I), a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to claim 1, wherein:

R⁵, R^{6a}, R^{6b}, R⁷, R⁸, R⁹, and R¹⁰ are hydrogens,

R¹ is hydrogen; C₁₋₆ alkyl; C₂₋₆ alkenyl; cycloalkylalkyl where the cycloalkyl moiety has 3 to 6 carbon atoms, and the alkylene moiety has 1 to 5 carbon atoms; or aralkyl where the aryl moiety has 6 to 10 carbon atoms, and the alkylene moiety has 1 to 5 carbon atoms,

R² is a 5- to 7-membered heterocyclic ring containing 1 to 4 heteroatoms selected from N, O and S and at least one carbon atom as ring-constituting atoms, containing at least one set of adjacent ring-constituting atoms bound by a double bond, and further substituted with at least one oxo group; or a heterocyclic ring consisting of the foregoing heterocyclic ring and a benzene ring condensed thereto, or pyridine 1-oxide.

R² binds to Y via a carbon atom of R² as a ring-constituting atom,

R³ and R⁴, which are the same or different, represent hydrogen; hydroxy; halogen; cyano; carbamoyl; C₁₋₆ alkoxy; C₆₋₁₀ aryloxy; C₁₋₆ alkanoyloxy; amino; or acylamino where the acyl moiety has 2 to 6 carbon atoms,

X is CH₂, and

Y is C(=O),

provided that the C₁₋₆ alkyl as R¹; the alkylene moiety and cycloalkyl moiety of the cycloalkylalkyl where the cycloalkyl moiety has 3 to 6 carbon atoms, and the alkylene moiety has 1 to 5 carbon atoms as R¹; and the alkylene moiety of the aralkyl where the aryl moiety has 6 to 10 carbon atoms, and the alkylene moiety has 1 to 5 carbon atoms as R¹ may be substituted with at least one substituent selected from

1 to 6 halogens; hydroxy; C₁₋₆ alkoxy; C₆₋₁₀ aryloxy; C₁₋₆ alkanoyl; C₁₋₆ alkanoyloxy; carboxyl; alkoxycarbonyl where the alkoxy moiety has 1 to 6 carbon atoms; carbamoyl;

alkylcarbamoyl where the alkyl moiety has 1 to 6 carbon atoms; dialkylcarbamoyl where each alkyl moiety has 1 to 6 carbon atoms; alkylsulfonyl where the alkyl moiety has 1 to 6 carbon atoms; aminosulfonyl; alkylsulfinyl where the alkyl moiety has 1 to 6 carbon atoms; alkylthio where the alkyl moiety has 1 to 6 carbon atoms; C₁₋₆ alkoxy substituted with 1 to 6 halogens; and arylcarbonyl where the aryl moiety has 6 to 10 carbon atoms,

the aryl moiety of the aralkyl where the aryl moiety has 6 to 10 carbon atoms, and the alkylene moiety has 1 to 5 carbon atoms as R¹; and the aryl moiety of the C₆₋₁₀ aryloxy as R³ or R⁴ may be substituted with at least one substituent selected from

C₁₋₆ alkyl; C₁₋₆ alkoxy; C₁₋₆ alkanoyloxy; hydroxy; alkoxycarbonyl where the alkoxy moiety has 1 to 6 carbon atoms; carbamoyl; alkylcarbamoyl where the alkyl moiety has 1 to 6 carbon atoms; dialkylcarbamoyl where each alkyl moiety has 1 to 6 carbon atoms; halogen; nitro; cyano; C₁₋₆ alkyl substituted with 1 to 3 halogens; C₁₋₆ alkoxy substituted with 1 to 3 halogens; phenyl; heteroaryl containing 1 to 4 heteroatoms selected from N, O and S as ring-constituting atoms; phenoxy; phenylalkyl where the alkyl has 1 to 3 carbon atoms; and methylenedioxy,

the heterocyclic ring as R² may have, besides the oxo group, at least one of the substituents which the aryl moiety of the aralkyl where the aryl moiety has 6 to 10 carbon atoms, and the alkylene moiety has 1 to 5 carbon atoms as R¹ may have, and

the alkylene moiety of the aralkyl where the aryl moiety has 6 to 10 carbon atoms, and the alkylene moiety has 1 to 5 carbon atoms as R¹ may be substituted with at least one substituent selected from phenyl, and C₁₋₆ alkyl substituted with 1 to 3 halogens.

[Claim ~~1131~~]

The compound, a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to claim ~~101 or 30~~, wherein R¹ is C₁₋₆ alkyl; cycloalkylalkyl where the cycloalkyl moiety has 3 to 6 carbon atoms, and the alkylene moiety has 1 to 5 carbon atoms; or aralkyl where the aryl moiety has 6 to 10 carbon atoms, and the alkylene moiety has 1 to 5 carbon atoms.

[Claim ~~1232~~]

The compound, a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to claim ~~101, 30, or 31~~, wherein R¹ is cycloalkylalkyl where the cycloalkyl moiety has 3 to 6 carbon atoms, and the alkylene moiety has 1 to 5 carbon atoms;

wherein R¹ is C₂₋₆ alkyl substituted with hydroxy; C₁₋₆ alkyl substituted with 1 to 6 halogens; or C₂₋₆ alkyl substituted with C₁₋₆ alkoxy; or

wherein R¹ is allyl, fluoropropyl, 2-(pyridin-3-yl)ethyl, 2-(methylsulfonyl)ethyl, or 2-(aminosulfonyl)ethyl;

~~[Claim 33]~~

~~—The compound, a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to claim 1 or 30, wherein R¹ is C₂₋₆ alkyl substituted with hydroxy; C₁₋₆ alkyl substituted with 1 to 6 halogens; or C₂₋₆ alkyl substituted with C₁₋₆ alkoxy.~~

~~[Claim 34]~~

~~—The compound, a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to claim 1 or 30, wherein R¹ is allyl, fluoropropyl, 2-(pyridin-3-yl)ethyl, 2-(methylsulfonyl)ethyl, or 2-(aminosulfonyl)ethyl.~~

~~[Claim 1335]~~

The compound, a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to any one of claims 1, and 10 to 12, and 30 to 34, wherein R² is pyridine 1-oxide, pyridin-2(1H)-one, pyridin-4(1H)-one, pyridazin-3(2H)-one, pyrazin-2(1H)-one, 4H-pyran-4-one, 2H-pyran-2-one, quinolin-2(1H)-one, pyrimidin-4(3H)-one, or pyrimidine-2,4(1H,3H)-dione, which may be substituted with a substituent selected from C₁₋₁₀ alkyl substituted with 1 to 3 fluorine atoms, and unsubstituted C₁₋₁₀ alkyl.

~~[Claim 1436]~~

The compound, a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to any one of claims 1, and 30 to 35 10 to 13, wherein R² is pyridine 1-oxide, which may be substituted with 1 to 4 substituents selected from C₁₋₁₀ alkyl and C₁₋₁₀ alkyl substituted with 1 to 3 fluorine atoms;

wherein R² is pyridin-2(1H)-one, which may be substituted with 1 to 4 substituents selected from C₁₋₁₀ alkyl and C₁₋₁₀ alkyl substituted with 1 to 3 fluorine atoms;

wherein R² is pyridin-4(1H)-one, which may be substituted with 1 to 4 substituents selected from C₁₋₁₀ alkyl substituted with 1 to 3 fluorine atoms, and unsubstituted C₁₋₁₀ alkyl;

wherein R² is pyridazin-3(2H)-one, which may be substituted with 1 to 3 substituents selected from C₁₋₁₀ alkyl substituted with 1 to 3 fluorine atoms, and unsubstituted C₁₋₁₀ alkyl;

wherein R² is pyrazin-2(1H)-one, which may be substituted with 1 to 3 substituents

selected from C₁₋₁₀ alkyl substituted with 1 to 3 fluorine atoms, and unsubstituted C₁₋₁₀ alkyl;
wherein R² is 4H-pyran-4-one, or 2H-pyran-2-one, which may be substituted with 1 to 3
substituents selected from C₁₋₁₀ alkyl substituted with 1 to 3 fluorine atoms, and unsubstituted
C₁₋₁₀ alkyl;
wherein R² is quinolin-2(1H)-one, which may be substituted with 1 to 3 substituents
selected from C₁₋₁₀ alkyl substituted with 1 to 3 fluorine atoms, and unsubstituted C₁₋₁₀ alkyl; or
wherein R² is pyrimidin-4(3H)-one, or pyrimidine-2,4(1H,3H)-dione, which may be
substituted with 1 to 3 substituents selected from C₁₋₁₀ alkyl substituted with 1 to 3 fluorine
atoms, and unsubstituted C₁₋₁₀ alkyl.

[Claim ~~1537~~]

The compound, a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to any one of claims ~~1, and 30 to 36,~~10 to 14,

wherein R² is pyridine 1-oxide;

wherein R² is pyridin-2(1H)-one; 1-(C₁₋₆ alkyl)pyridin-2(1H)-one; or 6-(C₁₋₆ alkyl)pyridin-
2(1H)-one;

wherein R² is pyridin-4(1H)-one, or 1-(C₁₋₆ alkyl)pyridin-4(1H)-one;

wherein R² is pyridazin-3(2H)-one;

wherein R² is pyrazin-2(1H)-one;

wherein R² is 4H-pyran-4-one, or 2H-pyran-2-one;

wherein R² is quinolin-2(1H)-one; or

wherein R² is pyrimidin-4(3H)-one, or pyrimidine-2,4(1H,3H)-dione.

[~~Claim 38~~]

~~—The compound, a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to any one of claims 1, and 30 to 35, wherein R² is pyridin-2(1H)-one, which may be substituted with 1 to 4 substituents selected from C₁₋₁₀ alkyl and C₁₋₁₀ alkyl substituted with 1 to 3 fluorine atoms.~~

[~~Claim 39~~]

~~—— The compound, a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to any one of claims 1, and 30 to 35, wherein R² is pyridin-2(1H)-one; 1-(C₁₋₆ alkyl)pyridin-2(1H)-one; or 6-(C₁₋₆ alkyl)pyridin-2(1H)-one.~~

~~[Claim 40]~~

~~—— The compound, a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to any one of claims 1, and 30 to 35, wherein R² is pyridin-4(1H)-one, which may be substituted with 1 to 4 substituents selected from C₁₋₁₀ alkyl substituted with 1 to 3 fluorine atoms, and unsubstituted C₁₋₁₀ alkyl.~~

~~[Claim 41]~~

~~—— The compound, a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to any one of claims 1, 30 to 35, and 40, wherein R² is pyridin-4(1H)-one, or 1-(C₁₋₆ alkyl)pyridin-4(1H)-one.~~

~~[Claim 42]~~

~~—— The compound, a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to any one of claims 1, and 30 to 35, wherein R² is pyridazin-3(2H)-one, which may be substituted with 1 to 3 substituents selected from C₁₋₁₀ alkyl substituted with 1 to 3 fluorine atoms, and unsubstituted C₁₋₁₀ alkyl.~~

~~[Claim 43]~~

~~—— The compound, a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to any one of claims 1, 30 to 35, and 42, wherein R² is pyridazin-3(2H)-one.~~

~~[Claim 44]~~

~~—— The compound, a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to any one of claims 1, and 30 to 35, wherein R² is pyrazin-2(1H)-one, which may be substituted with 1 to 3 substituents selected from C₁₋₁₀ alkyl substituted with 1 to 3 fluorine atoms, and unsubstituted C₁₋₁₀ alkyl.~~

~~[Claim 45]~~

~~—— The compound, a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to any one of claims 1, 30 to 35, and 44, wherein R² is pyrazin-2(1H)-one.~~

~~[Claim 46]~~

~~—— The compound, a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to any one of claims 1, and 30 to 35,~~

wherein R² is 4H-pyran-4-one, or 2H-pyran-2-one, which may be substituted with 1 to 3 substituents selected from C₁₋₁₀-alkyl substituted with 1 to 3 fluorine atoms, and unsubstituted C₁₋₁₀-alkyl.

[Claim 47]

— The compound, a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to any one of claims 1, 30 to 35, and 46, wherein R² is 4H-pyran-4-one, or 2H-pyran-2-one.

[Claim 48]

— The compound, a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to any one of claims 1, and 30 to 35, wherein R² is quinolin-2(1H)-one, which may be substituted with 1 to 3 substituents selected from C₁₋₁₀-alkyl substituted with 1 to 3 fluorine atoms, and unsubstituted C₁₋₁₀-alkyl.

[Claim 49]

— The compound, a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to any one of claims 1, 30 to 35, and 48, wherein R² is quinolin-2(1H)-one.

[Claim 50]

— The compound, a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to any one of claims 1, and 30 to 35, wherein R² is pyrimidin-4(3H)-one, or pyrimidine-2,4(1H,3H)-dione, which may be substituted with 1 to 3 substituents selected from C₁₋₁₀-alkyl substituted with 1 to 3 fluorine atoms, and unsubstituted C₁₋₁₀-alkyl.

[Claim 51]

— The compound, a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to any one of claims 1, 30 to 35, and 50, wherein R² is pyrimidin-4(3H)-one, or pyrimidine-2,4(1H,3H)-dione.

[Claim 1652]

The compound, a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to any one of claims 1, and 10 to 15, and 30 to 51, wherein one of R³ and R⁴ is hydroxy, and the other is hydrogen;

wherein R³ is halogen; cyano; carbamoyl; C₁₋₆ alkoxy; C₁₋₆ alkanoyloxy; amino; or acylamino where the acyl moiety has 2 to 6 carbon atoms, and R⁴ is hydrogen or hydroxy;

wherein R³ is hydroxy; carbamoyl; or C₁₋₆ alkanoyloxy, and R⁴ is hydrogen;

wherein R³ is hydroxy, and R⁴ is hydrogen; or

wherein R³ and R⁴ are hydrogens.

~~[Claim 53]~~

~~—The compound, a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to any one of claims 1, and 30 to 51, wherein R³ is halogen; cyano; carbamoyl; C₁₋₆ alkoxy; C₁₋₆ alkanoyloxy; amino; or acylamino where the acyl moiety has 2 to 6 carbon atoms, and R⁴ is hydrogen or hydroxy.~~

~~[Claim 54]~~

~~—The compound, a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to any one of claims 1, and 30 to 51, wherein R³ is hydroxy; carbamoyl; or C₁₋₆ alkanoyloxy, and R⁴ is hydrogen.~~

~~[Claim 55]~~

~~—The compound, a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to any one of claims 1, and 30 to 51, wherein R³ is hydroxy, and R⁴ is hydrogen.~~

~~[Claim 56]~~

~~—The compound, a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to any one of claims 1, and 30 to 51, wherein R³ and R⁴ are hydrogens.~~

[Claim 1757]

A compound according to claim 1 selected from:

2-((1S,3aR,5aS,6R,11bR,11cS)-14-(cyclopropylmethyl)-10-hydroxy-2,3,3a,4,5,6,7,11c-octahydro-1H-6,11b-(epiminoethano)-1,5a-methanonaphtho[1,2-e]indole-3-carbonyl)pyridine 1-oxide,

4-((1S,3aR,5aS,6R,11bR,11cS)-14-(cyclopropylmethyl)-10-hydroxy-2,3,3a,4,5,6,7,11c-octahydro-1H-6,11b-(epiminoethano)-1,5a-methanonaphtho[1,2-e]indole-3-carbonyl)pyridine 1-oxide,

3-((1S,3aR,5aS,6R,11bR,11cS)-14-(cyclopropylmethyl)-10-hydroxy-2,3,3a,4,5,6,7,11c-octahydro-1H-6,11b-(epiminoethano)-1,5a-methanonaphtho[1,2-e]indole-3-carbonyl)pyridine 2(1H)-one,

3-((1S,3aR,5aS,6R,11bR,11cS)-14-(cyclopropylmethyl)-10-hydroxy-2,3,3a,4,5,6,7,11c-octahydro-1H-6,11b-(epiminoethano)-1,5a-methanonaphtho[1,2-e]indole-3-carbonyl)pyridine 1-oxide,

5-((1S,3aR,5aS,6R,11bR,11cS)-14-(cyclopropylmethyl)-10-hydroxy-2,3,3a,4,5,6,7,11c-

octahydro-1H-6,11b-(epiminoethano)-1,5a-methanonaphtho[1,2-e]indole-3-carbonyl)pyridin-2(1H)-one,

3-((1S,3aR,5aS,6R,11bR,11cS)-14-(cyclopropylmethyl)-10-hydroxy-2,3,3a,4,5,6,7,11c-octahydro-1H-6,11b-(epiminoethano)-1,5a-methanonaphtho[1,2-e]indole-3-carbonyl)-1-methylpyridin-2(1H)-one,

6-((1S,3aR,5aS,6R,11bR,11cS)-14-(cyclopropylmethyl)-10-hydroxy-2,3,3a,4,5,6,7,11c-octahydro-1H-6,11b-(epiminoethano)-1,5a-methanonaphtho[1,2-e]indole-3-carbonyl)pyridin-2(1H)-one,

3-((1S,3aR,5aS,6R,11bR,11cS)-14-(cyclopropylmethyl)-10-hydroxy-2,3,3a,4,5,6,7,11c-octahydro-1H-6,11b-(epiminoethano)-1,5a-methanonaphtho[1,2-e]indole-3-carbonyl)-6-methylpyridin-2(1H)-one,

5-((1S,3aR,5aS,6R,11bR,11cS)-14-(cyclopropylmethyl)-10-hydroxy-2,3,3a,4,5,6,7,11c-octahydro-1H-6,11b-(epiminoethano)-1,5a-methanonaphtho[1,2-e]indole-3-carbonyl)-1-methylpyridin-2(1H)-one,

6-((1S,3aR,5aS,6R,11bR,11cS)-14-(cyclopropylmethyl)-10-hydroxy-2,3,3a,4,5,6,7,11c-octahydro-1H-6,11b-(epiminoethano)-1,5a-methanonaphtho[1,2-e]indole-3-carbonyl)-1-methylpyridin-2(1H)-one,

4-((1S,3aR,5aS,6R,11bR,11cS)-14-(cyclopropylmethyl)-10-hydroxy-2,3,3a,4,5,6,7,11c-octahydro-1H-6,11b-(epiminoethano)-1,5a-methanonaphtho[1,2-e]indole-3-carbonyl)pyridin-2(1H)-one,

5-((1S,3aR,5aS,6R,11bR,11cS)-14-(cyclopropylmethyl)-10-hydroxy-2,3,3a,4,5,6,7,11c-octahydro-1H-6,11b-(epiminoethano)-1,5a-methanonaphtho[1,2-e]indole-3-carbonyl)pyrimidine-2,4(1H,3H)-dione,

3-((1S,3aR,5aS,6R,11bR,11cS)-14-(cyclopropylmethyl)-10-hydroxy-2,3,3a,4,5,6,7,11c-octahydro-1H-6,11b-(epiminoethano)-1,5a-methanonaphtho[1,2-e]indole-3-carbonyl)pyridin-4(1H)-one,

2-((1S,3aR,5aS,6R,11bR,11cS)-14-(cyclopropylmethyl)-10-hydroxy-2,3,3a,4,5,6,7,11c-octahydro-1H-6,11b-(epiminoethano)-1,5a-methanonaphtho[1,2-e]indole-3-carbonyl)pyridin-4(1H)-one,

4-((1S,3aR,5aS,6R,11bR,11cS)-14-(cyclopropylmethyl)-10-hydroxy-2,3,3a,4,5,6,7,11c-octahydro-1H-6,11b-(epiminoethano)-1,5a-methanonaphtho[1,2-e]indole-3-carbonyl)-1-methylpyridin-2(1H)-one,

6-((1S,3aR,5aS,6R,11bR,11cS)-14-(cyclopropylmethyl)-10-hydroxy-2,3,3a,4,5,6,7,11c-octahydro-1H-6,11b-(epiminoethano)-1,5a-methanonaphtho[1,2-e]indole-3-carbonyl)pyridazin-

3(2H)-one,

4-((1S,3aR,5aS,6R,11bR,11cS)-14-(cyclopropylmethyl)-10-hydroxy-2,3,3a,4,5,6,7,11c-octahydro-1H-6,11b-(epiminoethano)-1,5a-methanonaphtho[1,2-e]indole-3-carbonyl)quinolin-2(1H)-one,

5-((1S,3aR,5aS,6R,11bR,11cS)-14-(cyclopropylmethyl)-10-hydroxy-2,3,3a,4,5,6,7,11c-octahydro-1H-6,11b-(epiminoethano)-1,5a-methanonaphtho[1,2-e]indole-3-carbonyl)-2H-pyran-2-one,

2-((1S,3aR,5aS,6R,11bR,11cS)-14-(cyclopropylmethyl)-10-hydroxy-2,3,3a,4,5,6,7,11c-octahydro-1H-6,11b-(epiminoethano)-1,5a-methanonaphtho[1,2-e]indole-3-carbonyl)-4H-pyran-4-one,

2-((1S,3aR,5aS,6R,11bR,11cS)-14-(cyclopropylmethyl)-10-hydroxy-2,3,3a,4,5,6,7,11c-octahydro-1H-6,11b-(epiminoethano)-1,5a-methanonaphtho[1,2-e]indole-3-carbonyl)-1-methylpyridin-4(1H)-one,

5-((1S,3aR,5aS,6R,11bR,11cS)-14-(cyclopropylmethyl)-10-hydroxy-2,3,3a,4,5,6,7,11c-octahydro-1H-6,11b-(epiminoethano)-1,5a-methanonaphtho[1,2-e]indole-3-carbonyl)pyrazin-2(1H)-one,

2-((1S,3aR,5aS,6R,11bR,11cS)-10-acetoxy-14-(cyclopropylmethyl)-2,3,3a,4,5,6,7,11c-octahydro-1H-6,11b-(epiminoethano)-1,5a-methanonaphtho[1,2-e]indole-3-carbonyl)pyridine 1-oxide,

6-((1S,3aR,5aS,6R,11bR,11cS)-14-(cyclopropylmethyl)-2,3,3a,4,5,6,7,11c-octahydro-1H-6,11b-(epiminoethano)-1,5a-methanonaphtho[1,2-e]indole-3-carbonyl)pyridin-2(1H)-one,

3-((1S,3aR,5aS,6R,11bR,11cS)-14-(cyclopropylmethyl)-10-hydroxy-2,3,3a,4,5,6,7,11c-octahydro-1H-6,11b-(epiminoethano)-1,5a-methanonaphtho[1,2-e]indole-3-carbonyl)pyrazin-2(1H)-one,

6-((1S,3aR,5aS,6R,11bR,11cS)-14-(cyclopropylmethyl)-10-hydroxy-2,3,3a,4,5,6,7,11c-octahydro-1H-6,11b-(epiminoethano)-1,5a-methanonaphtho[1,2-e]indole-3-carbonyl)pyrimidine-2,4(1H,3H)-dione,

6-((1S,3aR,5aS,6R,11bR,11cS)-14-(cyclopropylmethyl)-10-hydroxy-2,3,3a,4,5,6,7,11c-octahydro-1H-6,11b-(epiminoethano)-1,5a-methanonaphtho[1,2-e]indole-3-carbonyl)-1-ethylpyridin-2(1H)-one,

6-((1S,3aR,5aS,6R,11bR,11cS)-14-(cyclopropylmethyl)-10-hydroxy-2,3,3a,4,5,6,7,11c-octahydro-1H-6,11b-(epiminoethano)-1,5a-methanonaphtho[1,2-e]indole-3-carbonyl)pyrimidin-4(3H)-one, and

5-((1S,3aR,5aS,6R,11bR,11cS)-14-(cyclopropylmethyl)-10-hydroxy-2,3,3a,4,5,6,7,11c-

octahydro-1H-6,11b-(epiminoethano)-1,5a-methanonaphtho[1,2-e]indole-3-carbonyl)-1-ethylpyridin-2(1H)-one,

6-((1S,3a R,5aS,6R,11bR,11cS)-10-hydroxy-2,3,3a,4,5,6,7,11c-octahydro-1H-6,11b-(epiminoethano)-1,5a-methanonaphtho[1,2-e]indole-3-carbonyl)pyridin-2(1H)-one,

4-((1S,3aR,5aS,6R,11bR,11cS)-14-(cyclopropylmethyl)-10-hydroxy-2,3,3a,4,5,6,7,11c-octahydro-1H-6,11b-(epiminoethano)-1,5a-methanonaphtho[1,2-e]indole-3-carbonyl)-1-methyl-1,2-dihydro-3H-pyrazol-3-one,

5-chloro-3-((1S,3aR,5aS,6R,11bR,11cS)-14-(cyclopropylmethyl)-10-hydroxy-2,3,3a,4,5,6,7,11c-octahydro-1H-6,11b-(epiminoethano)-1,5a-methanonaphtho[1,2-e]indole-3-carbonyl)pyridin-2(1H)-one,

5-((1S,3aR,5aS,6R,11bR,11cS)-14-(cyclopropylmethyl)-10-hydroxy-2,3,3a,4,5,6,7,11c-octahydro-1H-6,11b-(epiminoethano)-1,5a-methanonaphtho[1,2-e]indole-3-carbonyl)-1,3-dimethylpyrimidine-2,4(1H,3H)-dione, and

6-((1S,3aR,5aS,6R,11bR,11cS)-14-(cyclopropylmethyl)-10-methoxy-2,3,3a,4,5,6,7,11c-octahydro-1H-6,11b-(epiminoethano)-1,5a-methanonaphtho[1,2-e]indole-3-carbonyl)pyridin-2(1H)-one,

a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof.

[Claim 18]

The compound, a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to claim 17, wherein the compound is 2-((1S,3aR,5aS,6R,11bR,11cS)-14-(cyclopropylmethyl)-10-hydroxy-2,3,3a,4,5,6,7,11c-octahydro-1H-6,11b-(epiminoethano)-1,5a-methanonaphtho[1,2-e]indole-3-carbonyl)pyridine 1-oxide.

[Claim 19]

The compound, a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to claim 17, wherein the compound is 3-((1S,3aR,5aS,6R,11bR,11cS)-14-(cyclopropylmethyl)-10-hydroxy-2,3,3a,4,5,6,7,11c-octahydro-1H-6,11b-(epiminoethano)-1,5a-methanonaphtho[1,2-e]indole-3-carbonyl)pyridin-2(1H)-one.

[Claim 20]

The compound, a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to claim 17, wherein the compound is 6-((1S,3aR,5aS,6R,11bR,11cS)-14-(cyclopropylmethyl)-10-hydroxy-2,3,3a,4,5,6,7,11c-octahydro-1H-6,11b-(epiminoethano)-1,5a-methanonaphtho[1,2-e]indole-3-carbonyl)pyridin-2(1H)-one.

[Claim 21]

The compound, a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to claim 17, wherein the compound is 5-((1S,3aR,5aS,6R,11bR,11cS)-14-(cyclopropylmethyl)-10-hydroxy-2,3,3a,4,5,6,7,11c-octahydro-1H-6,11b-(epiminoethano)-1,5a-methanonaphtho[1,2-e]indole-3-carbonyl)-1-methylpyridin-2(1H)-one.

[Claim 22]

The compound, a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to claim 17, wherein the compound is 6-((1S,3aR,5aS,6R,11bR,11cS)-14-(cyclopropylmethyl)-10-hydroxy-2,3,3a,4,5,6,7,11c-octahydro-1H-6,11b-(epiminoethano)-1,5a-methanonaphtho[1,2-e]indole-3-carbonyl)-1-methylpyridin-2(1H)-one.

[Claim 23]

The compound, a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to claim 17, wherein the compound is 5-((1S,3aR,5aS,6R,11bR,11cS)-14-(cyclopropylmethyl)-10-hydroxy-2,3,3a,4,5,6,7,11c-octahydro-1H-6,11b-(epiminoethano)-1,5a-methanonaphtho[1,2-e]indole-3-carbonyl)-1-ethylpyridin-2(1H)-one.

[Claim 24]

The compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to any one of claims 18 to 23.

[Claim 25]

The compound, or a pharmaceutically acceptable salt thereof according to claim 17.

[Claim 26]

The compound, or a pharmaceutically acceptable salt thereof according to claim 18.

[Claim 27]

The compound, or a pharmaceutically acceptable salt thereof according to claim 19.

[Claim 28]

The compound, or a pharmaceutically acceptable salt thereof according to claim 20.

[Claim 29]

The compound, or a pharmaceutically acceptable salt thereof according to claim 21.

[Claim 30]

The compound, or a pharmaceutically acceptable salt thereof according to claim 22.

[Claim 31]

The compound, or a pharmaceutically acceptable salt thereof according to claim 23.

~~[Claim 58]~~

~~—— A medicament comprising the compound, a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to any one of claims 1 to 57.~~

[Claim 3259]

A pharmaceutical composition comprising the compound, a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to any one of claims 1 to 3157 as an active ingredient.

[Claim 33]

The compound, a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to any one of claims 1 to 23 for the use of ameliorating, preventing or treating pain, anxiety, depression, Parkinson's disease, pollakiuria or urinary incontinence, or glaucoma.

[Claim 34]

The compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to any one of claims 24 to 31 for the use of ameliorating, preventing or treating pain, anxiety, depression, Parkinson's disease, pollakiuria or urinary incontinence, or glaucoma.

~~[Claim 60]~~

~~—— An analgesic comprising the compound, a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to any one of claims 1 to 57 as an active ingredient.~~

~~[Claim 61]~~

~~—— An antidepressant comprising the compound, a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to any one of claims 1 to 57 as an active ingredient.~~

~~[Claim 62]~~

~~—— An anxiolytic drug comprising the compound, a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to any one of claims 1 to 57 as an active ingredient.~~

~~[Claim 63]~~

~~—— A method for ameliorating, preventing or treating pain, which comprises administering an effective amount of the compound, a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to any one of claims 1 to 57.~~

~~[Claim 64]~~

~~— A method for ameliorating, preventing or treating depression, which comprises administering an effective amount of the compound, a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to any one of claims 1 to 57.~~

~~[Claim 65]~~

~~— A method for ameliorating, preventing or treating anxiety, which comprises administering an effective amount of the compound, a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to any one of claims 1 to 57.~~

~~[Claim 3366]~~

~~Use of t~~The compound, a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to any one of claims 1 to 23, 57 for the use of ameliorating, preventing or treating pain, anxiety, or depression, Parkinson's disease, pollakiuria or urinary incontinence, or glaucoma.

[Claim 34]

The compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to any one of claims 24 to 31 for the use of ameliorating, preventing or treating pain, anxiety, depression, Parkinson's disease, pollakiuria or urinary incontinence, or glaucoma.

~~[Claim 67]~~

~~— A method for ameliorating, preventing or treating pain, anxiety, or depression in a human, which comprises the step of administering an effective amount of the compound, a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to any one of claims 1 to 57 to the human.~~

~~[Claim 68]~~

~~— A therapeutic agent for Parkinson's disease comprising the compound, a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to any one of claims 1 to 57 as an active ingredient.~~

~~[Claim 69]~~

~~— A method for ameliorating, preventing or treating Parkinson's disease, which comprises administering an effective amount of the compound, a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to any one of claims 1 to 57.~~

~~[Claim 70]~~

~~Use of the compound, a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to any one of claims 1 to 57 for ameliorating, preventing or treating Parkinson's disease.~~

~~[Claim 71]~~

~~A method for ameliorating, preventing or treating Parkinson's disease in a human, which comprises the step of administering an effective amount of the compound, a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to any one of claims 1 to 57 to the human.~~

~~[Claim 72]~~

~~A therapeutic agent for pollakiuria or urinary incontinence comprising the compound, a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to any one of claims 1 to 57 as an active ingredient.~~

~~[Claim 73]~~

~~A method for ameliorating, preventing or treating pollakiuria or urinary incontinence, which comprises administering an effective amount of the compound, a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to any one of claims 1 to 57.~~

~~[Claim 74]~~

~~Use of the compound, a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to any one of claims 1 to 57 for ameliorating, preventing or treating pollakiuria or urinary incontinence.~~

~~[Claim 75]~~

~~A method for ameliorating, preventing or treating pollakiuria or urinary incontinence in a human, which comprises the step of administering an effective amount of the compound, a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to any one of claims 1 to 57 to the human.~~

~~[Claim 76]~~

~~A therapeutic agent for glaucoma comprising the compound, a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to any one of claims 1 to 57 as an active ingredient.~~

~~[Claim 77]~~

~~A method for ameliorating, preventing or treating glaucoma, which comprises administering an effective amount of the compound, a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to any~~

one of claims 1 to 57.

[Claim 78]

~~Use of the compound, a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to any one of claims 1 to 57 for ameliorating, preventing or treating glaucoma.~~

[Claim 79]

~~A method for ameliorating, preventing or treating glaucoma in a human, which comprises the step of administering an effective amount of the compound, a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to any one of claims 1 to 57 to the human.~~